Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-07 07:00 |
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Up…
|
English | 385.0 KB | ||
| 2025-05-07 07:00 |
Valneva publie ses résultats financiers du premier trimestre 2025 et fait un po…
|
French | 325.0 KB | ||
| 2025-04-26 19:10 |
Valneva fait un point sur la recommandation d’utilisation de son vaccin contre …
|
French | 206.8 KB | ||
| 2025-04-26 19:10 |
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by…
|
English | 182.3 KB | ||
| 2025-04-18 10:00 |
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCH…
|
English | 140.7 KB | ||
| 2025-04-18 10:00 |
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs améric…
|
French | 125.1 KB | ||
| 2025-04-16 17:45 |
Valneva participera à plusieurs événements lors du 25ème World Vaccine Congress…
|
French | 167.5 KB | ||
| 2025-04-16 17:45 |
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, i…
|
English | 186.2 KB | ||
| 2025-04-14 17:45 |
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya En…
|
English | 209.1 KB | ||
| 2025-04-14 17:45 |
Valneva reçoit la première autorisation de mise sur le marché pour IXCHIQ® dans…
|
French | 200.0 KB | ||
| 2025-04-09 07:00 |
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude …
|
French | 177.1 KB | ||
| 2025-04-09 07:00 |
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tet…
|
English | 200.0 KB | ||
| 2025-04-03 17:45 |
Valneva SE Shareholding Declaration - March 2025
|
English | 53.2 KB | ||
| 2025-04-03 17:45 |
Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2025
|
French | 159.3 KB | ||
| 2025-04-01 17:45 |
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged…
|
English | 248.1 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
